A modified Delphi consensus study to support and enhance Parkinson's disease management

Abstract

Background

Levodopa is still the cornerstone of symptomatic treatment for people with Parkinson's disease (PwP). With disease progression and long-term use, PwP can develop motor complications such as wearing off and dyskinesia. There is limited practical guidance on the early identification of motor fluctuations and the optimal timing of adjunctive therapies in clinical practice.

Objective

To develop expert consensus on best practices for initiating and monitoring levodopa therapy, recognising early motor fluctuations, incorporating adjunctive therapies, and improving patient education in the management of Parkinson's disease (PD).

Methods

A modified Delphi methodology was used. A steering committee (SC) of nine clinicians with experience in managing PD drafted 59 consensus statements across four thematic domains. Statements were developed into an online survey and distributed to a panel of UK-based healthcare professionals (HCPs). Respondents rated their agreement using a four-point Likert scale. Consensus was defined as ≥75% agreement.

Results

A total of 150 HCPs completed the survey, including neurologists, geriatricians, and PD nurse specialists. Consensus was achieved for all 59 statements (100%). Key areas of agreement included early alignment of treatment with individual patient goals, the need for routine monitoring using standardised tools, timely initiation of adjunctive therapies, and the importance of accessible, ongoing patient and caregiver education.

Conclusions

This Delphi consensus provides a set of expert-derived, clinically applicable recommendations to support proactive and individualised management of PD. Adoption of these practices may enhance the recognition and treatment of motor fluctuations, improve patient quality of life, and support better long-term outcomes.

Plain Language Summary Title

Experts agree on best practices for managing Parkinson's disease

Plain Language Summary

Why was the study done?

Levodopa is a key medicine for treating Parkinson's disease, helping with symptoms like stiffness and slow movement. Over time, though, some people notice changes in how well their medication works during the day. This can mean the effects wear off too soon or cause involuntary movements called dyskinesia.

Healthcare professionals do not have much practical guidance on how to spot these problems early, when to add new treatments, or how to best support people with Parkinson's and their caregivers.

This study brought experts together to create useful recommendations for better care.

What did the researchers do?

Nine UK experts who treat Parkinson's disease came up with 59 statements about different parts of care, like starting and monitoring levodopa, noticing early changes in movement, adding new medicines,and teaching patients and caregivers. They shared these statements with 150 healthcare professionals, including neurologists, geriatricians, and nurse specialists, who rated how much they agreed with each one. If 75% or more agreed, the statement was considered a consensus.

What did the researchers find?

All 59 statements reached full agreement from the group. The main recommendations were to start treatment based on each person's goals and needs, check symptoms regularly with standard tools, add new therapies at the right time to prevent problems, and make sure people with Parkinson's and their caregivers get ongoing, easy-to-understand education and support.

What do the findings mean?

The experts agreed on clear best practices to help healthcare professionals give more proactive and personalised care to people with Parkinson's disease. Using these recommendations may help spot movement problems sooner, improve symptom control, and boost patients' quality of life over time.

Keywords

Parkinson's disease levodopa motor fluctuations adjunctive therapy Delphi consensus wearing off

Introduction

The global number of people with Parkinson's disease (PwP) cases has been forecast to rise to 25.2 million by 2050, representing a 112% increase from 11.77 million in 2021.^1,2 Population aging was projected to account for 89% of this growth. Despite the growing incidence of Parkinson's disease (PD), a disease-modifying therapy able to slow down its progression is still lacking. Current treatment strategies for PwP include symptomatic treatments aimed at increasing dopamine availability, thereby helping to control symptoms and improve quality of life (QoL).

The National Institute for Health and Care Excellence (NICE) recommends the use of levodopa as the first-line treatment for PD motor symptoms.³ While motor symptoms are generally well controlled early in the disease, progression leads to the emergence of motor and non-motor fluctuations, including wearing off and early morning akinesia.^4–7 These complications often appear earlier than recognised and can substantially impact daily functioning.⁸

Strategies such as dose fractionation or increasing the total levodopa dose are commonly used but do not overcome the drug's short half-life and associated wearing off symptoms.⁹ Adjunctive therapies such as monoamine oxidase type B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors, and dopaminergic agonists (DAs) are recommended by NICE and the Movement Disorder Society (MDS) to optimise levodopa response.^3,10 Evidence suggests that some adjunctive therapies, such as COMT inhibitors, reduce “off” time more effectively than levodopa dose modification alone.^11,12

Despite these recommendations, current NICE and MDS guidelines provide limited practical direction on how and when to introduce adjunctive therapies, particularly in relation to early identification of wearing off, criteria for timely adjunct initiation, and structured monitoring of treatment response. This contributes to considerable variability in clinical practice.

This Delphi consensus sought to generate clear expert-driven recommendations on the use of adjunctive treatments, supported by pragmatic tools such as the 4-1-0 criteria to guide clinicians in recognising and managing levodopa wearing off complications. Additional aims included establishing consensus on other aspects of PD management, such as the initiation and monitoring of levodopa, early recognition of motor fluctuations, and best practices and education for the management of PD.

Methods

The process followed a modified Delphi methodology shown in Figure 1 and used ACCORD as a guideline for reporting the research.¹³

Figure 1.

Modified Delphi study design.

In November 2024, a brief literature review on the topic of enhancing PD disease management was performed using the PubMed database, which identified 42 relevant papers published between 2015 and 2024. Search terms included but were not limited to: “[Parkinson's Disease]”, “[Earlier treatment]”, “[Levodopa]”, “[COMT]”, “[MAO-B]”, “[Guideline]”, “[Treatment goals]”.

Guided by an independent facilitator, a steering committee (SC) of UK PD specialists, including four neurologists, two geriatricians, and three PD nurse specialists, convened in January 2025. The SC were selected based on published research, clinical experience in PD, and to provide a variety of perspectives across roles and the UK.

The information gathered from the literature review was used to inform the meeting discussion. As part of the discussion, the SC agreed on four main domains of focus:

Initiating and monitoring levodopa treatment

Recognition/identification of early motor fluctuations

Use of adjunctive therapies in levodopa

Best practices and education for management in PD

These domains were discussed in detail, and statements were suggested by the SC working collaboratively. Statements were independently reviewed by the SC and developed into a Likert survey. The survey was distributed by M3 Global Research, a market research company with a proprietary panel of verified healthcare professionals (HCPs). Eligible participants were neurologists, geriatricians, or PD nurse specialists based in the UK who were actively involved in the diagnosis and/or management of PwP. An equal distribution across the three professional roles was targeted to reflect a multidisciplinary perspective. Recruitment and dissemination were conducted entirely by M3 using their standard communication channels (e.g., email invitations and targeted outreach). In accordance with M3's policies, the number of HCPs invited and response-rate data were not disclosed to the study authors. Only completed responses were provided for analysis.

The identity of respondents was not known to the SC or the independent facilitator. The survey presented each statement along with a four-point Likert scale (‘strongly disagree’, ‘tend to disagree’, ‘tend to agree’, and ‘strongly agree’) to allow respondents to indicate their corresponding level of agreement. The survey also captured demographic data for further analysis, including occupation and time in role. All responses collected were included for the final analysis.

Stopping criteria were established a priori as a 4-week timeframe to collect responses, with a target of N = 150 responses, 90% of statements passing the threshold for consensus, with a threshold for consensus set at 75% (a widely accepted threshold).¹⁴

A statement of consent was included at the start of the survey, and consent was implied by completion. As this study only collected the anonymous opinions of HCPs and no patient-specific data were captured, ethical approval was not sought.

Anonymity of responders was planned into the study design. All responder data were captured by M3 Global. No personal information beyond occupation, time in role, and country was captured or provided to the independent facilitator (Triducive Partners).

The third party provided an incentive payment of an appropriate honorarium to panellists on the completion of survey response.

Analysis of survey data was carried out in April 2025. Completed surveys were analysed using Microsoft Excel software to produce an arithmetic agreement score for each statement. The responses were aggregated to provide an overall agreement level (i.e., the number of responses in agreement as a percentage of the overall number of responses). The SC reconvened in May 2025 for analysis and discussion of results. After review of the results, the SC agreed that no further rounds of survey were required due to the high levels of consensus across all statements.

Data availability statement

All anonymised data is included in the Supplemental Materials.

Results

A total of 150 survey responses were received and included in the final analysis. The statements and corresponding agreement levels are shown in Table 1 and depicted in Figure 2. Respondent demographics by role and time in role are detailed in Tables 2 and 3 , respectively. Breakdown of respondents’ agreement by role and region (country) is illustrated in Figures S1 and S2. Consensus was achieved for all 59 statements. As the stopping criteria were satisfied, no additional testing rounds were conducted. Distribution of consensus scores on the four-point Likert scale provided to respondents is represented in Figure S3.

Figure 2.

Consensus agreement levels by statement. The consensus threshold is depicted by the green line (75%).

Table 1.

Consensus statements and corresponding level of agreement.

No:	Statement	Strongly agree	Tend to agree	Tend to disagree	Strongly disagree	Agreement
Topic A: Initiating and monitoring levodopa treatment
1	Healthcare professionals (HCPs) should discuss each patient's individual goals of treatment, throughout their disease from the point of diagnosis, and ensure that treatment approaches are in line with these	78.67%	19.33%	0.00%	2.00%	98%
2	Patients should be educated and supported to make informed decisions about initiating levodopa treatment (including the benefits and possible side effects) at the point of diagnosis	75.33%	22.00%	1.33%	1.33%	97%
3	Levodopa is normally offered as the first-line treatment option for those in early stages of Parkinson's disease (PD) experiencing motor symptoms impacting on quality of life (QoL), in line with 2017 NICE guidance and patient preferences	58.67%	38.67%	2.00%	0.67%	97%
4	Non-pharmacological approaches e.g., recommending physical activity, may be considered in mild cases of PD before levodopa treatment is offered, but all patients should be counselled on the value of physical activity	53.33%	36.67%	8.00%	2.00%	90%
5	Patients should be reviewed at least every 6–12 months, either in person, or via specialist nurse telephone consultation (if in-person is not possible), depending on their clinical needs	68.67%	27.33%	3.33%	0.67%	96%
6	Standardised questionnaires such as the wearing off questionnaire (WOQ-19) or PART IV: Motor Complications of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) may be used to detect wearing off symptoms	43.33%	48.67%	7.33%	0.67%	92%
7	Non-motor symptom questionnaires may offer a more holistic view of the patient's symptoms (e.g., anxiety and depression) and should be routinely available	46.67%	42.00%	10.00%	1.33%	89%
8	Patient diaries can be a useful tool for tracking wearing off symptoms, but their reliability is limited due to their dependence on the patient/caregiver completing them correctly	45.33%	48.67%	6.00%	0.00%	94%
9	An adequate response to levodopa treatment can be defined as an improvement of symptoms, and should be judged on an individual basis	64.00%	33.33%	1.33%	1.33%	97%
10	In most patients, the response to levodopa changes over time, leading to wearing off symptoms and motor fluctuations with disease progression	56.67%	38.00%	4.00%	1.33%	95%
11	Long disease duration is a risk factor for levodopa wearing off	48.00%	45.33%	6.00%	0.67%	93%
12	While fractionating levodopa doses can be helpful in managing fluctuations, frequent dosing regimens may be associated with poor adherence	49.33%	42.67%	7.33%	0.67%	92%
13	Dopamine dysregulation can arise in patients frequently taking medication at high doses, and care should be taken to rationalise the patient's levodopa dose to avoid over-medication and associated risks	51.33%	42.67%	6.00%	0.00%	94%
14	In previously stable patients, motor fluctuations often emerge as the first sign of levodopa wearing off, and should be carefully assessed by the clinician or nurse specialist	48.67%	46.00%	4.00%	1.33%	95%
Topic B: Recognition/identification of early motor fluctuations
15	Patients and caregivers should be educated and empowered to recognise and report wearing off symptoms	66.67%	32.67%	0.67%	0.00%	99%
16	Motor fluctuations should be considered and assessed when patients report general malaise or “feeling worse”, particularly in the morning and/or during the night	49.33%	44.67%	5.33%	0.67%	94%
17	Distinguishing motor from non-motor symptoms is important to guide further treatment decisions	51.33%	44.00%	4.00%	0.67%	95%
18	Currently there is no single, validated, universal test or biomarker to detect and monitor motor fluctuations	44.67%	42.67%	12.00%	0.67%	87%
19	Motor fluctuations should be sought and assessed via detailed history-taking, supplemented where possible by an objective, validated measurement tool (e.g., wearable technology, standardised assessments or video recordings)	55.33%	41.33%	2.67%	0.67%	97%
20	Multiple perspectives involving caregivers can be helpful for clinicians to gain a comprehensive understanding of a patient's wearing off symptoms, recognising that symptoms vary during the day, and between days	50.00%	43.33%	6.67%	0.00%	93%
21	The use of technology to assess treatment response may be helpful, but there are few validated tools, and these are not implemented consistently across the NHS, due to the variety of devices available, and access and cost limitations	38.67%	56.67%	4.00%	0.67%	95%
22	Mobile applications (apps) have not been shown to be effective for assessing treatment response in routine clinical practice	27.33%	47.33%	25.33%	0.00%	75%
23	Wearable devices are generally more effective than apps to assess treatment response, as they gather information passively without requiring input from the patient or caregiver, but they require careful calibration and validation	31.33%	56.67%	12.00%	0.00%	88%
24	Wearable devices, including a smartwatch and accelerometer, may be useful for assessing treatment response if they are integrated into therapy early, but require further validation in clinical trials and research settings	35.33%	56.67%	7.33%	0.67%	92%
25	The results from wearable devices should not be a substitute for taking clinical history, as these devices can perform poorly at identifying sudden or disabling off periods	57.33%	35.33%	7.33%	0.00%	93%
26	There must be greater consistency in how wearable devices are used to assess symptom burden by HCPs across the UK, if they are to be adopted widely in the management of PD	56.00%	39.33%	4.00%	0.67%	95%
27	A shared language should be developed at the point of diagnosis to ensure patients and HCPs communicate effectively around PD symptoms	52.67%	42.67%	4.67%	0.00%	95%
28	Clear written information from a trusted source, with an explanation of wearing off symptoms, and how to detect and monitor them, should be shared with patients and caregivers when any new treatment is prescribed	57.33%	38.00%	4.00%	0.67%	95%
29	Patients should be signposted to educational resources (e.g., Parkinson's UK website, local support groups) to enhance their understanding of symptom progression and management	70.00%	28.67%	0.67%	0.67%	99%
30	HCPs should be aware that non-specific or imperfectly defined symptoms (e.g., “feeling worse”) may represent motor or non-motor wearing off symptoms	57.33%	38.00%	3.33%	1.33%	95%
31	Patients may be unaware that wearing off symptoms can be improved with treatment adjustments	42.67%	52.00%	5.33%	0.00%	95%
32	Symptoms observed in clinic by HCPs do not always reflect the patient's lived experience, which can delay the detection of wearing off symptoms	49.33%	44.00%	6.67%	0.00%	93%
33	Patients with comorbidities (e.g., dementia) may struggle to recognise, detect and communicate wearing off symptoms	62.67%	32.00%	5.33%	0.00%	95%
34	Patients with communication or language barriers may find it difficult to effectively communicate their symptoms to clinicians	61.33%	36.00%	2.00%	0.67%	97%
35	Access to a PD nurse specialist may be limited in some areas, restricting the detection and management of wearing off symptoms	57.33%	36.67%	5.33%	0.67%	94%
36	Many patients are not seen frequently enough (e.g., every 6–12 months), with appointment times often short (i.e., 15 min), which can prevent the detection and understanding of wearing off symptoms	47.33%	46.00%	6.00%	0.67%	93%
37	Patients often see a different HCP at each appointment, which may hinder accurate information-gathering and sharing, and patient care	38.00%	48.00%	13.33%	0.67%	86%
38	Early detection and intervention for wearing off symptoms supports patient and caregiver education, enabling them to better recognise changes in symptoms and can potentially improve patient outcomes, but this requires further research	60.67%	36.67%	2.67%	0.00%	97%
39	Early detection and intervention for wearing off symptoms may improve patients’ overall QoL	63.33%	32.00%	4.67%	0.00%	95%
40	Early detection and intervention support HCPs in providing personalised treatment options, which may include adjunctive therapies such as COMT inhibitors	54.67%	40.67%	4.00%	0.67%	95%
41	More research is needed to better understand the impact of early identification and treatment of motor fluctuations on functioning and QoL	62.00%	35.33%	1.33%	1.33%	97%
Topic C: Use of adjunctive therapies in levodopa
42	Adjunctive therapies (e.g., COMT inhibitors) can be considered when a patient does not achieve an adequate response to an appropriate dose of levodopa	54.00%	44.00%	2.00%	0.00%	98%
43	Adjunctive therapies (e.g., COMT inhibitors) should be considered when wearing off symptoms begin to impact a patient's QoL	48.00%	48.67%	3.33%	0.00%	97%
44	A “4-1-0” criteria (4 doses per day; 1 h of off time per day; either with or without the presence of dyskinesias) should be used as a clinical guide for identifying the early stages of motor fluctuations, and the potential need for an adjunctive therapy	34.00%	54.67%	10.67%	0.67%	89%
45	Patients commenced on adjunctive therapies may need to adjust other medications and should be educated and supported in this	52.00%	45.33%	2.67%	0.00%	97%
46	Early use of adjunctive therapies can lead to more time in the on state, leading to improved QoL when a patient is wearing off	42.67%	52.67%	3.33%	1.33%	95%
47	Early use of adjunctive therapies can lead to improved motor control, fewer motor fluctuations and less off time, although more research is required	51.33%	42.00%	6.67%	0.00%	93%
48	Treatment with COMT inhibitors can support levodopa sparing, which is optimal in the management of PD	47.33%	46.00%	6.67%	0.00%	93%
49	Treatment with MAO-B inhibitors can support levodopa sparing, which is optimal in the management of PD	36.67%	56.00%	6.00%	1.33%	93%
50	The addition of longer-acting adjunctive therapies, such as COMT inhibitors, may result in more favourable outcomes for patients in comparison to fractioning levodopa (e.g., to 4–5 doses a day)	41.33%	52.00%	6.67%	0.00%	93%
51	The addition of longer-acting adjunctive therapies, such as MAO-B inhibitors, may result in more favourable outcomes for patients in comparison to fractioning levodopa (e.g., to 4–5 doses a day)	37.33%	52.00%	10.00%	0.67%	89%
52	Patients on levodopa and adjunctive therapies should be assessed every 6–12 months to understand response to treatment and support optimal management, either in person or via telephone consultation	58.00%	38.00%	2.00%	2.00%	96%
53	A positive response to treatment can be characterised by improvements in motor fluctuations and dyskinesias as recognised by standardised assessments (e.g., WOQ-19, MDS-UPDRS) and patient history	58.00%	36.67%	5.33%	0.00%	95%
Topic D: Best practice and education for the management of PD
54	All patients should have access to a specialist PD clinic or specialist clinician for the duration of their disease	80.00%	17.33%	2.67%	0.00%	97%
55	All patients should be prescribed adjunctive therapies as early as possible to prevent issues, in line with 2017 NICE guidance	50.00%	42.67%	6.00%	1.33%	93%
56	All patients should be given the opportunity to learn about all aspects of PD, throughout their disease from the point of diagnosis, through simple, accessible communication to help support their own treatment decisions	72.00%	25.33%	2.00%	0.67%	97%
57	All patients should have access to rehabilitation services and psychological support when required	68.67%	27.33%	3.33%	0.67%	96%
58	Increased awareness and research are required to understand how PD impacts women, particularly as symptoms can be confounded by menarchal and/or menopausal symptoms	64.00%	29.33%	6.00%	0.67%	93%
59	PD nurses should undertake the non-medical prescribing qualification as part of their role to support effective and timely management of PwP	58.00%	31.33%	10.00%	0.67%	89%

Table 2.

Number of respondents by role.

Role	Neurologist	Geriatrician	PD nurse specialist
N=	50	50	50

Table 3.

Number of respondents by time in role.

Time in role	≤5 years	6–10 years	11–20 years	>20 years
N=	16	56	59	19

Table 4.

Consensus recommendations and possible clinical implications.

Recommendation	Clinical implications
1. Treatment decisions in PD should be aligned with individual patient goals, and patients and caregivers should be educated about PD treatments and signs of wearing off from the point of diagnosis.	Encourages personalised care from the earliest stages of PD; improves patient and caregiver understanding, enabling earlier reporting of symptom changes and more effective shared decision-making.
2. Levodopa should be offered as first-line pharmacological therapy for PwP, alongside consideration of non-pharmacological approaches such as physical activity.	Reinforces evidence-based first-line treatment while highlighting the importance of holistic management; supports integration of lifestyle measures that may improve long-term functioning and QoL.
3. Patients should be reviewed for motor and non-motor symptoms at least every 6–12 months (i.e., at every appointment) to ensure the early detection of motor fluctuations and wearing off.	Standardises review intervals across clinical settings, reducing variability in follow-up frequency; supports earlier identification of treatment complications and need for therapeutic adjustment.
4. Patients should be assessed using several evaluation tools, including validated questionnaires or standardised clinical questioning, detailed history-taking and an objective measurement tool where feasible.	Promotes comprehensive, multimodal assessment to improve diagnostic accuracy; reduces reliance on subjective impressions and helps detect subtle or early symptom changes.
5. Adjunctive therapies should be initiated as early as clinically appropriate, with 4-1-0 criteria used as a clinical guide to support the management of levodopa wearing off complications.	Provides a simple and pragmatic tool to guide consistent, timely escalation beyond levodopa monotherapy; may prevent prolonged periods of uncontrolled symptoms and associated functional decline.
6. All patients with PD should have equitable access to appropriate specialist care, pharmacological treatments and multidisciplinary rehabilitation services. Further research is also required to understand sex-specific differences and the impact of PD on women.	Highlights systemic barriers impacting real-world care; encourages health-system-level improvements in access and equity, while underscoring areas where evidence gaps remain (e.g., the specific needs of women with PD).

The SC discussed the results and agreed on a set of recommendations for best practices in PD management.

Discussion

This Delphi consensus has provided a set of expert-derived, clinically applicable recommendations to support proactive and individualised management of PD (Table 4). Below, we discuss each recommendation and summarise the published literature that supports the consensus. Recommendation 1:

Treatment decisions in PD should be aligned with individual patient goals, and patients and caregivers should be educated about PD treatment and signs of wearing off from the point of diagnosis.

Evidence suggests that targeting therapy towards specific treatment goals leads to better physical function than standardised approaches. A randomised controlled trial (RCT) by Cabrera-Martos et al. demonstrated that PwP who received a goal-directed intervention achieved significantly greater improvements in both goal attainment and manual dexterity compared to those receiving standard therapy.¹⁵ Several machine-learning-based tools have been tested to personalise medication strategies for patients.^16–18 A recent study sought to advance personalised PD medicine through an algorithm that analyses sequential patient visit data and provides subsequent recommendations.^19,20 It was concluded that consideration of personal medication history can significantly enhance decision-making for altering medication strategy. Furthermore, a secondary analysis of goal-setting interventions in PD found that treatment decisions should be aligned with patient-defined goals, which covered a diverse range of themes underscoring the multifaceted needs of PwP.²⁰

Poor concordance is closely linked to the complexity of dosing schedules and a lack of patient understanding. Empowering patients through targeted education and ensuring alignment of treatment goals with individual preferences has been shown to improve adherence and outcomes.²¹ Education programmes, such as the Patient Education Programme Parkinson (PEPP), have demonstrated efficacy at improving health-related quality of life (HRQOL) for patients and carers through eight 90-min education sessions. A multicentre RCT by Chlond et al. involving 64 PwP and 46 caregivers evaluated its efficacy.²² The intervention group participated in an 8-week programme and demonstrated significantly improved HRQOL at 3-month follow-up, measured using the Parkinson's disease quality of life questionnaire (PDQ-39). Similar effects were demonstrated by A’Campo et al., measured using the severity of dependence scale (SDS).²³ In scenarios where a formal programme may not be practical, these consensus results suggest that all patients should be signposted to external educational resources (e.g., Parkinson's UK website, local support groups) for additional guidance. Recommendation 2:

Levodopa should be offered as first-line therapy for PwP, alongside consideration of non-pharmacological approaches such as physical activity.

According to this Delphi consensus, levodopa remains the preferred first-line treatment option for patients with early-stage PD who experience motor symptoms impacting QoL, as recommended by NICE in 2017.³ This consensus defined an adequate response to levodopa treatment as an improvement of motor symptoms, which should be judged on a case-by-case basis, given the heterogeneity of the disease. In most patients, the response to levodopa changes over time as disease progression occurs. This can lead to early wearing off in PwP whose disease state rapidly deteriorates.²⁴ Education on all aspects of levodopa treatment, including early wearing off, is therefore critical to empower patients to recognise and report early signs and facilitate assessment for levodopa adjustment or adjunctive treatments.

We strongly advocate that all PwP, regardless of disease stage, should be considered and educated on the value of physical activity. There is comprehensive RCT evidence supporting the long-term effectiveness of physical activity on outcome measures for PwP.^25–27 As little as six months of aerobic exercise can attenuate off-state motor signs as measured by the Motor Complications of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS).²⁷ Furthermore, a 6-month intensive exercise programme was shown to increase dopamine transporter availability in the substantia nigra and putamen.²⁸ Finally, exercise has been shown to promote increased dopamine release and subsequently preserve motor and non-motor function.²⁹ Recommendation 3:

Patients should be reviewed for motor and non-motor symptoms at least every 6–12 months (i.e., every appointment) to ensure the early detection of motor fluctuations and wearing off.

In addition to empowering patients to detect their own wearing off symptoms, regular clinical review enables HCPs to detect these changes early and adjust treatment accordingly.³⁰ This recommendation is consistent with current guidance from NICE and Parkinson's UK, which advocates for reviews every 6–12 months to monitor disease progression and treatment response.^31,32

Evidence suggests that wearing off can emerge earlier in the disease course than previously assumed. One recent RCT defined ‘early’ wearing off as experiencing at least 1 h of daily “off” time for a minimum of 4 weeks, but for less than two years.¹¹ Similarly, the DEEP observational study reported that up to 41.8% of PwP with disease duration under 2.5 years experienced wearing off, assessed via the wearing off questionnaire (WOQ-19).⁸

This consensus emphasised the critical role of early detection in optimising PD management. Early identification of wearing off allows HCPs to personalise treatment strategies, potentially improving symptom control and QoL. Respondents also agreed that early recognition supports patient and caregiver education by empowering them to better recognise changes in their symptoms. The authors note that further research is needed to clearly define the parameters of ‘early’ detection and confirm its impact on long-term outcomes.³³ Recommendation 4:

Patients should be assessed using several evaluation tools, including validated questionnaires or standardised clinical questioning, detailed history-taking and an objective measurement tool where feasible.

Given the likelihood of developing motor complications, consistent review and monitoring of symptoms are critical. Standardised, validated questionnaires, such as the WOQ-19, the MDS-UPDRS, and non-motor symptom questionnaires, can be used during reviews to detect wearing off symptoms. However, the SC noted that these tools are applied inconsistently in clinical practice, with some HCPs, particularly PD nurses and physiotherapists, using tailored sets of questions developed and refined through clinical experience.

There is currently no single, validated objective measure or biomarker to detect and monitor motor fluctuations. Yet, findings indicate that incorporating one objective measurement into PD management enhances both motor and non-motor outcomes.³⁴ As such, this consensus explored alternative methods for the accurate tracking of wearing off symptoms. The SC agreed that detailed history-taking, which may include the use of patient diaries capturing multiple perspectives (e.g., from caregivers), should be supplemented by one or more objective measurement tools.

Wearable devices, including smartwatches and accelerometers, were deemed useful for contributing towards the clinical assessment of motor symptoms and treatment response if integrated into therapy early. Body-worn sensors could provide valuable data, with summarised scores for bradykinesia, dyskinesia, and tremor shown to be associated with suggested treatment modifications.³⁵ In this consensus, mobile applications were deemed less favourable due to the burden of regular symptom logging. This can be challenging for many patients, particularly those with cognitive impairment, and may limit the accuracy and completeness of data collection. Due to the multitude of devices and applications available, the SC stressed the need for consistency in their use and the analysis of data generated. Taken together, these findings highlight important unmet needs and priority areas for future research. The development and validation of reliable biomarkers, alongside standardised and user-friendly digital tools, will be critical to improving early detection and monitoring of motor fluctuations.

This consensus identified several additional barriers to the accurate assessment of symptoms in PD. Patients with comorbidities may struggle to recognise, detect and communicate wearing off signs and symptoms, while patients with communication or language barriers may find it difficult to effectively communicate their symptoms to clinicians. Reports of general malaise or ‘feeling worse’ should prompt clinicians to assess for motor fluctuation, as these may be indicative of wearing off.

It was also acknowledged that symptoms observed during clinic visits do not always reflect the patient's lived experience, potentially delaying recognition and management of wearing off symptoms. Patients may misinterpret wearing off symptoms as a sign that levodopa is no longer effective or that their disease is progressing, whilst being unaware that treatment adjustments can often alleviate such issues.

Infrastructural challenges further complicate symptom assessment. These include limited access to PD nurse specialists in some areas, irregular patient visits (e.g., >12 months), short appointment times (i.e., 15 min), and a lack of continuity of care when patients see different HCPs at each visit, which can hinder accurate information-gathering and sharing. Recommendation 5:

Adjunctive therapies should be initiated as early as clinically appropriate, with 4-1-0 criteria used as a clinical guide to support the management of levodopa wearing off complications.

Although adjustments in levodopa administration, such as fractionation, can be helpful to manage symptoms, frequent dosing regimens may be associated with poor medication concordance.³⁶ Additionally, dopamine dysregulation can arise in patients taking levodopa in high dosages, and so care must be taken to avoid over-medication and its associated risks. Levodopa sparing is an optimal strategy to mitigate these risks and can be supported with adjunctive therapies such as COMT or MAO-B inhibitors. This consensus confirmed views that the addition of adjunctive therapies may result in more favourable outcomes compared to fractioning levodopa.

NICE recommends that adjuvant therapy should be offered to patients who develop motor fluctuations or dyskinesia despite optimal levodopa therapy.³ The results of this study reinforce this guidance by suggesting that adjunctive therapies should be considered as early as clinically appropriate, when a patient does not achieve an adequate response to an optimal dose of levodopa, and when wearing off symptoms begin to impact QoL. Clinician-perceived benefits of early adjunctive intervention were improved motor control and fewer fluctuations, leading to less time in the off state.

However, existing guidelines provide no specific criterion to determine when it is clinically appropriate to introduce adjunctive therapy. A previous Delphi consensus study defined the ‘5-2-1’ criteria for defining advanced PD, which have already been used to identify eligible subjects for device-aided therapies in longitudinal studies.^37,38 Satisfying the criteria includes five levodopa doses per day, having at least 2 h of “off” time per day, or having at least 1 h of dyskinesia.³⁹ This criterion was used as a conceptual starting point by the SC to develop a novel ‘4-1-0’ rule of four levodopa doses per day, one hour of “off” time per day, with or without the presence of dyskinesias, as a clinical guide for identifying early stages of motor fluctuations and the potential need for adjunctive therapy. The 4-1-0 criteria were coined by the Steering Committee with the specific aim of providing a simple tool to be used by HCPs in clinical practice for the early identification of motor fluctuations in PD patients. While an 89% agreement was achieved among the wider expert panel, the criteria certainly needs a full validation in real-world clinical practice. However, they were formulated on a strong rationale and indirect evidence from published studies.

Five-times daily oral levodopa doses or more are already considered per se an indicator of advanced PD and eligibility for device-aided therapies.³⁷ It was, therefore, thought that the occurrence of “off” time despite four oral levodopa doses could be a valid criterion to identify people with early fluctuations who could potentially benefit from adjunctive therapies. Furthermore, a recent study has shown that in PD patients with early fluctuations on three to four intakes of levodopa, the adjunct of a long-acting COMT inhibitor was superior to an additional daily levodopa dose in reducing wearing off.¹¹

OFFELIA (OFF episode quality of life impact scale) has recently been proposed as a new measure of quality of life for “off” episodes in PD.⁴⁰ In the validation study, the duration of individual “off” periods was categorised and episodes lasting less than one hour were common (less than 15 min = 8.6%; between 15 and 30 min = 28.8%; between 30 and 45 min = 22%; between 45 min and 1 h = 27.2%), highlighting the need for proactive screening even for short-lasting fluctuations. In another large cohort of 722 PD patients, the vast majority (94%) of patients with “off” episodes experienced one to five hours of daily “off” time.⁴¹ Interestingly, the presence of an “off” period significantly affected measures of quality of life regardless of the average hours of daily “off” time, implying that even one hour of “off” time could have a detectable impact on quality of life. Considering that all adjunctive drug classes effectively reduce “off” time by 0.8–1.5 h per day, an early introduction of these drugs could provide a full benefit and functional gain in these patients.⁴²

The proposed criterion of minimal or no dyskinesias is mechanistically rational, as the aim of the criteria is to identify patients with early motor fluctuations who could benefit from adjunctive therapy even before the occurrence of other motor complications.⁴² Therefore, patients who fulfil the previous two criteria but have no or minimal dyskinesia are more likely to experience the greatest benefit from adjunctive therapy without the onset or worsening of dyskinesia.

Consensus also supported that longer-acting adjunctive therapies, such as COMT inhibitors and MAO-B inhibitors, may result in more favourable outcomes for patients compared to fractioning levodopa (e.g., to 4–5 doses per day). Data from various RCTs have demonstrated the superior efficacy of adjunctive COMT therapy versus levodopa fractionation.^11,12 Therefore, longer-acting adjunctive therapies should be considered as early as clinically appropriate, rather than adjusting the dose of levodopa.

Despite these benefits, access to adjunctive therapies for PD in the UK and Europe remains inconsistent. This variability is influenced by multiple factors, including regional differences, the availability of pharmacological agents within each therapeutic class and prescribing practices of HCPs.⁴³ For example, the SC highlighted that although the current NICE guidance recommends a range of adjunctive options, local formularies and commissioning arrangements often restrict the availability of specific agents. In addition, there is inconsistent access to different COMT inhibitors across commissioners, resulting in regional variation in prescribing practices. Due to limited UK and international guidance on when and how to introduce adjunctive therapies into the treatment pathway, prescribing practices are often subjective and depend on clinicians’ attitudes and knowledge.

Addressing these disparities is necessary to ensure equitable care for individuals with PD. To achieve this, targeted training and case studies on the latest evidence surrounding adjunctive therapies should be provided to HCPs to support consistent adoption of evidence-based treatment strategies. Moreover, standardising guidance on when and how to introduce adjunctive therapies would promote consistent prescribing practices and reduce regional variation in care. Recommendation 6:

All patients with PD should have equitable access to appropriate specialist care, pharmacological treatments and multidisciplinary rehabilitation services. Further research is also required to understand sex-specific differences and the impact of PD on women.

According to Parkinson's UK, there is a shortage of approximately 100 PD specialist nurses across the UK, corroborating this consensus where respondents agreed that access to a PD nurse specialist may be limited in some areas, potentially restricting the detection and management of wearing off symptoms.⁴⁴ To ensure the provision of equitable care, this should be addressed.

Efforts should also be made to ensure equitable access to treatments and medications across all regions, so that all patients can benefit from holistic and individualised patient-centred care. A recent analysis of UK prescribing data from 2019–2024 showed that prescribing patterns for PD vary substantially.⁴⁵ While levodopa was found to be the most commonly prescribed drug in England, Scotland, and Wales, DAs were more frequently used in Northern Ireland. This disparity is thought to reflect differences in demographics, healthcare infrastructure, and economic factors. Therefore, addressing these disparities is an important step toward equitable access to holistic treatments for PD and improved patient-centred care.

In addition, all PwP should have access to appropriate multidisciplinary rehabilitation services, including disease-specific physiotherapy, occupational therapy, speech and language therapy and psychological support as necessary. Consistent with this consensus, an international statement concluded that a multidisciplinary rehabilitative approach is an essential component of comprehensive treatment of PD and should encompass discipline-specific support services across all PD stages.⁴⁶

Lastly, this consensus also highlighted that increased awareness and research are required to understand how PD impacts women, as symptoms can be confounded by menarcheal and/or menopausal symptoms. This represents an important yet often overlooked aspect of PD management that should be recognised and addressed.

Strengths and limitations

This study achieved consensus from a large sample of 150 specialist clinicians across multiple UK regions, thus making the findings strong and generalisable. A structured, modified Delphi methodology was used, ensuring rigour and reproducibility of the methods. Consensus was achieved for all statements, providing a strong evidence base for the given recommendations. This study only included one round of survey; however, this was deemed sufficient since the stopping criteria were met. Self-reported data can also be subject to recall bias and subjectivity. Additionally, the survey was only completed by HCPs, and the patient perspective may be particularly helpful in strengthening the utility of these findings. Finally, as with all Delphi processes, participants may have adjusted their responses to align with perceived group consensus, which could lead to bias.

Conclusions

This modified Delphi consensus achieved agreement from a panel of 150 HCPs involved in PD management for all 59 statements, offering a unified expert perspective in an area where practical guidance has been limited. The findings have clear implications for clinical practice, encouraging earlier recognition of motor fluctuations and more consistent assessment of symptoms, with an emphasis on the fact that wearing off often occurs sooner than traditionally assumed. Regularly scheduled reviews supported by validated questionnaires, detailed clinical questioning, and objective tools can help clinicians detect changes earlier and intervene more effectively. The consensus also supports earlier initiation of adjunctive therapies, guided by the 4-1-0 criteria, which offer a simple and actionable framework to reduce subjectivity and regional variability in prescribing decisions. By promoting timely intervention and more structured follow-up, these consensus recommendations help address existing gaps and support a more proactive, standardised approach that may improve long-term outcomes and quality of life for PwP.

Supplemental Material

sj-jpeg-1-pkn-10.1177_1877718X261427577 - Supplemental material for A modified Delphi consensus study to support and enhance Parkinson's disease management

Supplemental material, sj-jpeg-1-pkn-10.1177_1877718X261427577 for A modified Delphi consensus study to support and enhance Parkinson's disease management by N Pavese, J Evans, A Hand, EJ Newman, G Duncan, H Martin, L Ebenezer, B Mohamed, E Lassman, J Barnett and F Morgante in Journal of Parkinson's Disease

Supplemental Material

sj-jpeg-2-pkn-10.1177_1877718X261427577 - Supplemental material for A modified Delphi consensus study to support and enhance Parkinson's disease management

Supplemental material, sj-jpeg-2-pkn-10.1177_1877718X261427577 for A modified Delphi consensus study to support and enhance Parkinson's disease management by N Pavese, J Evans, A Hand, EJ Newman, G Duncan, H Martin, L Ebenezer, B Mohamed, E Lassman, J Barnett and F Morgante in Journal of Parkinson's Disease

Supplemental Material

sj-jpeg-3-pkn-10.1177_1877718X261427577 - Supplemental material for A modified Delphi consensus study to support and enhance Parkinson's disease management

Supplemental material, sj-jpeg-3-pkn-10.1177_1877718X261427577 for A modified Delphi consensus study to support and enhance Parkinson's disease management by N Pavese, J Evans, A Hand, EJ Newman, G Duncan, H Martin, L Ebenezer, B Mohamed, E Lassman, J Barnett and F Morgante in Journal of Parkinson's Disease

Footnotes

Acknowledgements

The authors wish to thank Emily Lassman and James Barnett from Triducive Partners Limited for their support in collating the data, analysing the results, writing the manuscript, and reviewing the final draft.

ORCID iDs

A Hand

G Duncan

H Martin

B Mohamed

J Barnett

Authors’ contributions

All views expressed by the authors are those of the individual and do not represent those of their organisation/place of work. Contributors NP, JE, AH, EJN, GD, HM, LE, BM, and FM agreed on the design of the study, formulated and reviewed the statement set. Results of the study were discussed by all contributors as part of a formal Steering Group meeting, where commentary was agreed for development into the initial draft manuscript. NP, JE, AH, EJN, GD, HM, LE, BM, and FM took an equal role in reviewing the initial manuscript draft and providing comments, and all approved the final draft.

Ethics approval and consent to participate

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Funding

The study was initiated and funded by BIAL. All authors received funding from BIAL while undertaking this study. BIAL commissioned Triducive Partners Limited to facilitate the project and analyse the responses to the consensus statements in line with the Delphi methodology. Triducive Partners Limited provided an incentive payment of an appropriate honorarium to panellists on the completion of survey response. After engaging Triducive Partners Limited, BIAL made no contribution to the design and development of the study outside of payment of honoraria. BIAL took no part in the writing, revision or editing of the manuscript except to check that the manuscript contained no promotion of specific medicines and that all recommendations were appropriate to drug label.

Declaration of conflicting interests

All authors received honoraria from BIAL while undertaking this study. BIAL commissioned Triducive Partners Limited to facilitate the project and analyse the responses to the consensus statements in line with the Delphi methodology.

The authors state the following conflicts of interest:

GD has received speaker fees from GE Healthcare, BIAL and AbbVie, and honoraria for advisory boards and consulting from BIAL and AbbVie.

HM has received honoraria for consultancy and educational meetings from BIAL, AbbVie, and Merz Pharma.

NP has received honoraria from BIAL, Britannia Pharmaceuticals, AbbVie, GE Healthcare, Boston Scientific, been a part of advisory boards for Hoffmann-La Roche, BIAL, AbbVie, Teva, Biohaven, and Teitur Trophics, and received grants from Independent Research Fund Denmark, Danish Parkinson's disease Association, Parkinson's UK, Center of Excellence in Neurodegeneration (CoEN) network award, GE Healthcare Grant, Multiple System Atrophy Trust, Weston Brain Institute, EU Joint Program Neurodegenerative Disease Research (JPND), EU Horizon 2020 research, The Michael J. Fox Foundation, F. Hoffmann-La Roche, Medtronic, and Symbyx.

FM has received consultancy fees from Boston Scientific and Medtronic, been a part of advisory boards for AbbVie, Boston Scientific, Merz Pharma, Medtronic and Roche, received speaking honoraria from AbbVie, Boston Scientific, Merz Pharma, Medtronic, Teva, Ipsen, International Parkinson's Disease and Movement Disorders Society, royalties from Springer, and research support from the National Institute for Health and Care Research, Innovate UK and Merz Pharma.

JE has received speaker and consultancy fees from BIAL, Zambon, AbbVie, Ipsen, Britannia Pharmaceuticals, and Kyowa Kirin, and conference subsistence support from BIAL, AbbVie, Ipsen, Britannia Pharmaceuticals, and UCB.

EJN has received travel bursaries or speaker fees from the following companies: AbbVie, BIAL, Britannia Pharmaceuticals, Ipsen, Medtronic, and Merz Pharma.

Availability of data and materials

All data relevant to the study are included in the article or uploaded as .

Declarations

The study was not prospectively registered, as neither the assigned interventions nor the outcomes assessed were related to the health of participants.

Supplemental material

Supplemental material for this article is available online.

References

Cui

, et al. Projections for prevalence of Parkinson’s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. Br Med J 2025; 388: e080952.

Luo

Qiao

, et al. Global, regional, national epidemiology and trends of Parkinson’s disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021. Front Aging Neurosci 2024; 16: 1498756.

Parkinson’s disease | Treatment summaries | BNF | NICE, https://bnf.nice.org.uk/treatment-summaries/parkinsons-disease/#drug-treatment (2017, accessed 25 June 2025).

Aradi

Hauser

. Medical management and prevention of motor complications in Parkinson’s disease. Neurotherapeutics 2020; 17: 1339–1365.

Espay

Morgante

Merola

, et al. Levodopa-induced dyskinesia in Parkinson disease: current and evolving concepts. Ann Neurol 2018; 84: 797–811.

Surmeier

. Determinants of dopaminergic neuron loss in Parkinson’s disease. FEBS J 2018; 285: 3657–3668.

Chou

Stacy

Simuni

, et al.

The spectrum of “off” in Parkinson’s disease: what have we learned over 40 years?

Parkinsonism Relat Disord 2018; 51: 9–16.

Stocchi

Antonini

Barone

, et al. Early DEtection of wEaring off in Parkinson disease: the DEEP study. Parkinsonism Relat Disord 2014; 20: 204–211.

Brooks

. Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatr Dis Treat 2008; 4: 39.

10.

Fox

Katzenschlager

Lim

, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord 2018; 33: 1248–1266.

11.

Ferreira

Lee

, et al. Opicapone for the treatment of early wearing-off in levodopa-treated Parkinson’s disease: pooled analysis of patient level data from two randomized open-label studies. J Neurol 2024; 271: 6729–6738.

12.

Ferreira

Poewe

Rascol

, et al. Effect of opicapone on levodopa pharmacokinetics in patients with fluctuating Parkinson’s disease. Mov Disord 2022; 37: 2272–2283.

13.

Gattrell

Logullo

van Zuuren

, et al. ACCORD (ACcurate COnsensus Reporting Document): a reporting guideline for consensus methods in biomedicine developed via a modified Delphi. PLoS Med 2024; 21: e1004326.

14.

Diamond

Grant

Feldman

, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol 2014; 67: 401–409.

15.

Cabrera-Martos

Ortiz-Rubio

Torres-Sánchez

, et al. A randomized controlled study of whether setting specific goals improves the effectiveness of therapy in people with Parkinson’s disease. Clin Rehabil 2019; 33: 465–472.

16.

Abdo

Gallay

Vallecillo

, et al. A machine learning-based clinical predictive tool to identify patients at high risk of medication errors. Sci Rep 2024; 14: 1–11.

17.

Kim

Lee

. Medication recommendation for Parkinson’s disease based on dynamics of symptom progression. Sci Rep 2024; 14: 1–12.

18.

Kim

Suescun

Schiess

, et al. Computational medication regimen for Parkinson’s disease using reinforcement learning. Sci Rep 2021; 11: 1–9.

19.

Riasi

Delrobaei

Salari

. Personalized medication recommendations for Parkinson’s disease patients using gated recurrent units and SHAP interpretability. Sci Rep 2025; 15: 1–12.

20.

Kang

Jethani

Foster

. Person-centered goal setting is feasible in people with Parkinson’s disease who have subjective cognitive decline. Arch Phys Med Rehabil 2022; 103: e9.

21.

Grosset

. Patient-perceived involvement and satisfaction in Parkinson’s disease: effect on therapy decisions and quality of life. Mov Disord 2005; 20: 616–619.

22.

Chlond

Bergmann

Güthlin

, et al. Patient education for patients with Parkinson’s disease: a randomised controlled trial. Basal Ganglia 2016; 6: 25–30.

23.

A’Campo

LEI

Wekking

Spliethoff-Kamminga

NGA

, et al. The benefits of a standardized patient education program for patients with Parkinson’s disease and their caregivers. Parkinsonism Relat Disord 2010; 16: 89–95.

24.

Stocchi

Jenner

Obeso

. When do levodopa motor fluctuations first appear in Parkinson’s disease? Eur Neurol 2010; 63: 257–266.

25.

Schenkman

Hall

Baron

, et al. Exercise for people in early- or mid-stage Parkinson disease: a 16-month randomized controlled trial. Phys Ther 2012; 92: 1395–1410.

26.

Tsukita

Sakamaki-Tsukita

Takahashi

. Long-term effect of regular physical activity and exercise habits in patients with early Parkinson disease. Neurology 2022; 98: E859–E871.

27.

van der Kolk

de Vries

Kessels

RPC

, et al. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson’s disease: a double-blind, randomised controlled trial. Lancet Neurol 2019; 18: 998–1008.

28.

de Laat

Hoye

Stanley

, et al. Intense exercise increases dopamine transporter and neuromelanin concentrations in the substantia Nigra in Parkinson’s disease. NPJ Parkinsons Dis 2024; 10: 1–7.

29.

Sacheli

Murray

Vafai

, et al. Habitual exercisers versus sedentary subjects with Parkinson’s disease: multimodal PET and fMRI study. Mov Disord 2018; 33: 1945–1950.

30.

Caillava-Santos

Margis

de Mello Rieder

. Wearing-off in Parkinson’s disease: neuropsychological differences between on and off periods. Neuropsychiatr Dis Treat 2015; 11: 1175.

31.

Parkinson’s UK. Patient initiated follow up/review.

32.

Follow-up checks | Information for the public | Parkinson’s disease in adults | Guidance | NICE, https://www.nice.org.uk/guidance/ng71/ifp/chapter/Follow-up-checks#:∼:text=If%20you%20are%20diagnosed%20with,every%206%20to%2012%20months (2017, accessed 26 June 2025).

33.

Pérez-López

Samà

Rodríguez-Martín

, et al. Assessing motor fluctuations in Parkinson’s disease patients based on a single inertial sensor. Sensors (Basel) 2016; 16: 2132.

34.

Woodrow

Horne

Fernando

, et al. A blinded, controlled trial of objective measurement in Parkinson’s disease. NPJ Parkinsons Dis 2020; 6: 1–10.

35.

Virbel-Fleischman

Mousin

Liu

, et al. Symptoms assessment and decision to treat patients with advanced Parkinson’s disease based on wearables data. NPJ Parkinsons Dis 2023; 9: 1–10.

36.

Tinelli

Kanavos

Grimaccia

. The value of early diagnosis and treatment in Parkinson’s disease: a literature review of the potential clinical and socioeconomic impact of targeting unmet needs in Parkinson’s disease. 2016.

37.

Antonini

Stoessl

Kleinman

, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Curr Med Res Opin 2018; 34: 2063–2073.

38.

Ledingham

Sathyanarayana

Stewart

, et al. Tracking motor progression and device-aided therapy eligibility in Parkinson’s disease. Ann Clin Transl Neurol 2025; 13: 1–14.

39.

Aldred

Anca-Herschkovitsch

Antonini

, et al. Application of the a ‘5-2-1’ screening criteria in advanced Parkinson’s disease: interim analysis of DUOGLOBE. Neurodegener Dis Manag 2020; 10: 309–323.

40.

Kuharic

Kulbokas

Hanson

, et al. OFF Episode quality of life impact scale (OFFELIA): a new measure of quality of life for off episodes in Parkinson’s disease. Parkinsonism Relat Disord 2024; 123: 106070. Epub ahead of print 1 June 2024.

41.

Thach

Jones

Pappert

, et al. Real-world assessment of the impact of “OFF” episodes on health-related quality of life among patients with Parkinson’s disease in the United States. BMC Neurol 2021; 21: 46.

42.

Sisodia

Dubbeld

De Bie

RMA

, et al. Efficacy and safety of adjunctive oral therapy in Parkinson’s disease with motor complications: a systematic review and network meta-analysis. BMJ Neurol Open 2024; 6: e000573. Epub ahead of print 10 February 2024.

43.

Hansen

Witzig

Schulz

, et al. Dopaminergic treatment strategies for people with Parkinson’s disease in Europe: a retrospective analysis of PRISM trial data. Neurol Sci 2023; 44: 3905–3912.

44.

People with Parkinson’s can’t wait any longer | Parkinson’s UK, https://www.parkinsons.org.uk/news/people-parkinsons-cant-wait-any-longer (accessed 29 June 2025).

45.

Orayj

. Trends in Parkinson’s disease medication prescribing patterns in the UK: an interrupted time series analysis (2019–2024). PLoS One 2025; 20: e0324999.

46.

Goldman

Volpe

Ellis

, et al. Delivering multidisciplinary rehabilitation care in Parkinson’s disease: an international consensus statement. J Parkinsons Dis 2024; 14: 135–166.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.71 MB

0.00 MB

0.36 MB